PT3293176T - Forma cristalina de um inibidor de pde4 - Google Patents
Forma cristalina de um inibidor de pde4Info
- Publication number
- PT3293176T PT3293176T PT171922784T PT17192278T PT3293176T PT 3293176 T PT3293176 T PT 3293176T PT 171922784 T PT171922784 T PT 171922784T PT 17192278 T PT17192278 T PT 17192278T PT 3293176 T PT3293176 T PT 3293176T
- Authority
- PT
- Portugal
- Prior art keywords
- crystal form
- pde4 inhibitor
- pde4
- inhibitor
- crystal
- Prior art date
Links
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
- C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C205/59—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13189784 | 2013-10-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3293176T true PT3293176T (pt) | 2021-03-03 |
Family
ID=49385193
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT147955652T PT3060551T (pt) | 2013-10-22 | 2014-10-17 | Processo para a preparação de um inibidor de pde4 |
PT171922784T PT3293176T (pt) | 2013-10-22 | 2014-10-17 | Forma cristalina de um inibidor de pde4 |
PT191830165T PT3587400T (pt) | 2013-10-22 | 2014-10-17 | Processo para a preparação de um inibidor de pde4 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT147955652T PT3060551T (pt) | 2013-10-22 | 2014-10-17 | Processo para a preparação de um inibidor de pde4 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT191830165T PT3587400T (pt) | 2013-10-22 | 2014-10-17 | Processo para a preparação de um inibidor de pde4 |
Country Status (30)
Country | Link |
---|---|
US (7) | US9434691B2 (pt) |
EP (5) | EP3060551B1 (pt) |
JP (5) | JP6458957B2 (pt) |
KR (3) | KR102287598B1 (pt) |
CN (3) | CN114621139A (pt) |
AR (4) | AR098128A1 (pt) |
AU (1) | AU2014339136C1 (pt) |
BR (1) | BR112016008161B1 (pt) |
CA (3) | CA3115587A1 (pt) |
CY (1) | CY1123811T1 (pt) |
DK (3) | DK3587400T3 (pt) |
ES (2) | ES2857629T3 (pt) |
FI (1) | FI3587400T3 (pt) |
HK (1) | HK1223926A1 (pt) |
HR (2) | HRP20192152T1 (pt) |
HU (2) | HUE053112T2 (pt) |
IL (4) | IL285532B2 (pt) |
LT (2) | LT3293176T (pt) |
MX (4) | MX370104B (pt) |
MY (1) | MY182559A (pt) |
PH (2) | PH12016500737A1 (pt) |
PL (3) | PL3060551T3 (pt) |
PT (3) | PT3060551T (pt) |
RS (2) | RS65452B1 (pt) |
RU (1) | RU2682660C9 (pt) |
SG (4) | SG10202112587RA (pt) |
SI (3) | SI3587400T1 (pt) |
TW (3) | TWI720803B (pt) |
UA (2) | UA127453C2 (pt) |
WO (1) | WO2015059050A1 (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6004233B2 (ja) | 2010-08-03 | 2016-10-05 | チェシ ファーマスーティシ エス.ピー.エイ. | ホスホジエステラーゼ阻害剤を含む乾燥粉末製剤 |
EP3060551B1 (en) | 2013-10-22 | 2019-09-18 | Chiesi Farmaceutici S.p.A. | Process for the preparation of a pde4 inhibitor |
EP3487501A1 (en) * | 2016-07-20 | 2019-05-29 | Allergan, Inc. | Methods, compositions, and compounds for treatment of dermatological and ocular conditions |
JP7361584B2 (ja) * | 2018-12-19 | 2023-10-16 | 高砂香料工業株式会社 | アミドの還元によるアミンの製造方法 |
JP6780763B2 (ja) | 2018-12-25 | 2020-11-04 | トヨタ自動車株式会社 | 内燃機関の制御装置 |
US11149615B2 (en) | 2018-12-25 | 2021-10-19 | Toyota Jidosha Kabushiki Kaisha | Control device for internal combustion engine |
CN111808029A (zh) * | 2020-08-31 | 2020-10-23 | 兰晟生物医药(苏州)有限公司 | 一种pde4抑制剂氯比普兰的制备方法 |
CN118475343A (zh) | 2021-12-21 | 2024-08-09 | 凯西制药公司 | 填充在具有改善的耐湿性的吸入器中的干粉制剂 |
WO2023208982A1 (en) | 2022-04-27 | 2023-11-02 | Chiesi Farmaceutici S.P.A. | Crystal form of a pde4 inhibitor |
CN115304542B (zh) * | 2022-07-18 | 2024-02-02 | 湖南华纳大药厂手性药物有限公司 | 一种3-羟基吡啶的合成工艺 |
WO2024027901A1 (en) | 2022-08-02 | 2024-02-08 | Chiesi Farmaceutici S.P.A. | Predictive biomarker of clinical response to a pde4 inhibitor |
WO2024062005A1 (en) | 2022-09-22 | 2024-03-28 | Chiesi Farmaceutici S.P.A. | Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor |
WO2024062006A1 (en) | 2022-09-22 | 2024-03-28 | Chiesi Farmaceutici S.P.A. | Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor |
WO2024062007A1 (en) | 2022-09-22 | 2024-03-28 | Chiesi Farmaceutici S.P.A. | Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5935978A (en) * | 1991-01-28 | 1999-08-10 | Rhone-Poulenc Rorer Limited | Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group |
EP1276745B1 (en) * | 2000-03-30 | 2011-01-12 | Chirotech Technology Limited | Ruthenium-diphosphine complexes and their use as catalysts |
EP1670742A1 (en) * | 2003-09-12 | 2006-06-21 | Ranbaxy Laboratories Limited | Process for the preparation of roflumilast |
PL1740593T3 (pl) | 2004-04-19 | 2016-09-30 | Sposoby wytwarzania wodorosiarczanu klopidogrelu w formie polimorficznej I | |
ATE459618T1 (de) * | 2004-04-29 | 2010-03-15 | Aventis Pharma Inc | 3-piperidinylisochroman-5-ole als dopaminagonisten |
KR20070079278A (ko) | 2006-02-01 | 2007-08-06 | 삼성전자주식회사 | 수신자 제한 시스템을 이용하는 디지털 멀티미디어시스템에서 수신기의 채널 전환 시간 단축 장치 및 방법 |
ATE496029T1 (de) * | 2006-07-14 | 2011-02-15 | Chiesi Farma Spa | Derivate von 1-phenyl-2-pyridinylalkylenalkohole als phosphodiesteraseinhibitoren |
DK2125736T3 (da) * | 2006-12-22 | 2011-07-11 | Leo Pharma As | Substituerede acetophenoner egnede som PDE4-inhibitorer |
EP2022783A1 (en) | 2007-08-08 | 2009-02-11 | CHIESI FARMACEUTICI S.p.A. | "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors" |
US20100015430A1 (en) | 2008-07-16 | 2010-01-21 | Outlast Technologies, Inc. | Heat Regulating Article With Moisture Enhanced Temperature Control |
EP2216327A1 (en) * | 2009-02-06 | 2010-08-11 | CHIESI FARMACEUTICI S.p.A. | Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors |
EP2580195B1 (en) | 2010-06-14 | 2014-12-03 | Chiesi Farmaceutici S.p.A. | Crystal form of glycopyrronium chloride |
CN103052378A (zh) * | 2010-08-03 | 2013-04-17 | 奇斯药制品公司 | 包含磷酸二酯酶抑制剂的药物制剂 |
JP6004233B2 (ja) * | 2010-08-03 | 2016-10-05 | チェシ ファーマスーティシ エス.ピー.エイ. | ホスホジエステラーゼ阻害剤を含む乾燥粉末製剤 |
EP2643322B1 (en) | 2010-11-23 | 2017-08-30 | Abbvie Inc. | Salts and crystalline forms of an apoptosis-inducing agent |
CN103827088B (zh) * | 2011-09-26 | 2017-10-13 | 奇斯药制品公司 | 作为磷酸二酯酶抑制剂的1‑苯基‑2‑吡啶基烷基醇的衍生物 |
AR089232A1 (es) | 2011-12-16 | 2014-08-06 | Chiesi Farma Spa | Potenciacion inducida por inhibidores de pde4 en el tratamiento de la leucemia |
EP2928869B1 (en) * | 2012-12-05 | 2019-02-20 | Chiesi Farmaceutici S.p.A. | 1-phenyl-2-pyridinyl alkyl alcohol derivatives as phosphodiesterase inhibitors |
US9427376B2 (en) * | 2013-10-10 | 2016-08-30 | Chiesi Farmaceutici S.P.A. | Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient |
EP3060551B1 (en) * | 2013-10-22 | 2019-09-18 | Chiesi Farmaceutici S.p.A. | Process for the preparation of a pde4 inhibitor |
KR101591785B1 (ko) | 2013-12-24 | 2016-02-04 | 주식회사 투게더 | 데이터 입력 장치, 이를 이용한 데이터 전송 시스템 및 방법 |
BR112020012972A2 (pt) * | 2017-12-28 | 2020-11-24 | Chiesi Farmaceutici S.P.A. | uso de derivados de álcool 1-fenil-2-piridinil alquílico para tratar fibrose cística |
CN118475343A (zh) * | 2021-12-21 | 2024-08-09 | 凯西制药公司 | 填充在具有改善的耐湿性的吸入器中的干粉制剂 |
-
2014
- 2014-10-17 EP EP14795565.2A patent/EP3060551B1/en active Active
- 2014-10-17 CN CN202210366235.7A patent/CN114621139A/zh active Pending
- 2014-10-17 SG SG10202112587RA patent/SG10202112587RA/en unknown
- 2014-10-17 ES ES17192278T patent/ES2857629T3/es active Active
- 2014-10-17 ES ES14795565T patent/ES2759514T3/es active Active
- 2014-10-17 PT PT147955652T patent/PT3060551T/pt unknown
- 2014-10-17 WO PCT/EP2014/072334 patent/WO2015059050A1/en active Application Filing
- 2014-10-17 EP EP20207308.6A patent/EP3798209A1/en active Pending
- 2014-10-17 PT PT171922784T patent/PT3293176T/pt unknown
- 2014-10-17 PL PL14795565T patent/PL3060551T3/pl unknown
- 2014-10-17 CA CA3115587A patent/CA3115587A1/en active Pending
- 2014-10-17 SI SI201432068T patent/SI3587400T1/sl unknown
- 2014-10-17 AU AU2014339136A patent/AU2014339136C1/en active Active
- 2014-10-17 CA CA2928242A patent/CA2928242C/en active Active
- 2014-10-17 IL IL285532A patent/IL285532B2/en unknown
- 2014-10-17 EP EP19183016.5A patent/EP3587400B1/en active Active
- 2014-10-17 HU HUE17192278A patent/HUE053112T2/hu unknown
- 2014-10-17 US US14/516,976 patent/US9434691B2/en active Active
- 2014-10-17 UA UAA201909177A patent/UA127453C2/uk unknown
- 2014-10-17 EP EP22169035.7A patent/EP4059921A1/en active Pending
- 2014-10-17 PT PT191830165T patent/PT3587400T/pt unknown
- 2014-10-17 FI FIEP19183016.5T patent/FI3587400T3/fi active
- 2014-10-17 KR KR1020217004799A patent/KR102287598B1/ko active IP Right Grant
- 2014-10-17 CN CN201480058065.XA patent/CN105658629B/zh active Active
- 2014-10-17 EP EP17192278.4A patent/EP3293176B1/en active Active
- 2014-10-17 SG SG10201912852YA patent/SG10201912852YA/en unknown
- 2014-10-17 LT LTEP17192278.4T patent/LT3293176T/lt unknown
- 2014-10-17 LT LTEP19183016.5T patent/LT3587400T/lt unknown
- 2014-10-17 DK DK19183016.5T patent/DK3587400T3/da active
- 2014-10-17 CN CN201910622800.XA patent/CN110256338A/zh active Pending
- 2014-10-17 UA UAA201604362A patent/UA121853C2/uk unknown
- 2014-10-17 DK DK17192278.4T patent/DK3293176T3/da active
- 2014-10-17 HU HUE14795565A patent/HUE046637T2/hu unknown
- 2014-10-17 RU RU2016115246A patent/RU2682660C9/ru active
- 2014-10-17 JP JP2016519348A patent/JP6458957B2/ja active Active
- 2014-10-17 DK DK14795565T patent/DK3060551T3/da active
- 2014-10-17 SG SG11201603130TA patent/SG11201603130TA/en unknown
- 2014-10-17 RS RS20240463A patent/RS65452B1/sr unknown
- 2014-10-17 SG SG10201903575UA patent/SG10201903575UA/en unknown
- 2014-10-17 SI SI201431364T patent/SI3060551T1/sl unknown
- 2014-10-17 SI SI201431775T patent/SI3293176T1/sl unknown
- 2014-10-17 CA CA3115570A patent/CA3115570C/en active Active
- 2014-10-17 PL PL19183016.5T patent/PL3587400T3/pl unknown
- 2014-10-17 PL PL17192278T patent/PL3293176T3/pl unknown
- 2014-10-17 BR BR112016008161-7A patent/BR112016008161B1/pt active IP Right Grant
- 2014-10-17 KR KR1020217004798A patent/KR102287596B1/ko active IP Right Grant
- 2014-10-17 KR KR1020167010773A patent/KR102240865B1/ko active IP Right Review Request
- 2014-10-17 RS RS20210247A patent/RS61558B1/sr unknown
- 2014-10-17 MX MX2016004834A patent/MX370104B/es active IP Right Grant
- 2014-10-17 MY MYPI2016000681A patent/MY182559A/en unknown
- 2014-10-20 AR ARP140103938A patent/AR098128A1/es active IP Right Grant
- 2014-10-20 TW TW109102549A patent/TWI720803B/zh active
- 2014-10-20 TW TW107133858A patent/TWI685486B/zh active
- 2014-10-20 TW TW103136112A patent/TWI651305B/zh active
-
2016
- 2016-04-14 MX MX2022000036A patent/MX2022000036A/es unknown
- 2016-04-14 MX MX2019014408A patent/MX2019014408A/es unknown
- 2016-04-14 MX MX2022000030A patent/MX2022000030A/es unknown
- 2016-04-20 IL IL245220A patent/IL245220A/en active IP Right Grant
- 2016-04-20 PH PH12016500737A patent/PH12016500737A1/en unknown
- 2016-07-22 US US15/217,468 patent/US9890122B2/en active Active
- 2016-10-20 HK HK16112131.7A patent/HK1223926A1/zh unknown
-
2017
- 2017-06-11 IL IL252834A patent/IL252834B/en unknown
- 2017-11-03 US US15/802,737 patent/US10323003B2/en active Active
-
2018
- 2018-10-05 JP JP2018189627A patent/JP2019038813A/ja active Pending
-
2019
- 2019-04-23 US US16/391,952 patent/US10759761B2/en active Active
- 2019-11-29 HR HRP20192152TT patent/HRP20192152T1/hr unknown
-
2020
- 2020-01-22 PH PH12020500162A patent/PH12020500162A1/en unknown
- 2020-02-17 AR ARP200100438A patent/AR118124A2/es unknown
- 2020-07-21 US US16/934,527 patent/US11352327B2/en active Active
- 2020-10-14 JP JP2020173216A patent/JP7051970B2/ja active Active
-
2021
- 2021-02-15 CY CY20211100122T patent/CY1123811T1/el unknown
- 2021-03-01 HR HRP20210336TT patent/HRP20210336T1/hr unknown
- 2021-05-27 AR ARP210101430A patent/AR122182A2/es unknown
- 2021-05-27 AR ARP210101431A patent/AR122183A2/es unknown
- 2021-08-11 IL IL285528A patent/IL285528A/en unknown
-
2022
- 2022-02-22 JP JP2022025240A patent/JP7345581B2/ja active Active
- 2022-02-22 JP JP2022025300A patent/JP7534346B2/ja active Active
- 2022-05-06 US US17/738,630 patent/US11981639B2/en active Active
-
2024
- 2024-01-02 US US18/401,832 patent/US20240166605A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL285528A (en) | A process for preparing a pde4 inhibitor | |
HK1221224A1 (zh) | 依洛昔巴特的結晶修飾物 | |
EP2951711A4 (en) | TIME OF DISPLAY OF AN INTERNET PAGE | |
ZA201702252B (en) | A selective inhibitor of prosphatidylinositol 3-kinase-gamma | |
GB201317609D0 (en) | Inhibitor compounds | |
HRP20190564T1 (hr) | Sol i kristalni oblici inhibitora plk-4 | |
EP3020718A4 (en) | NOVEL PDE4 INHIBITOR | |
HK1222339A1 (zh) | 金屬-β-內酰胺酶的抑制劑 | |
GB201321328D0 (en) | Inhibitor compounds | |
GB201305503D0 (en) | Inhibitor |